Alexander Lossos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexander Lossos has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Oded Abramsky
Department of Neurology and the Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel
7 shared publicationsZohar Argov
Department of Neurology and the Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel
7 shared publicationsHanna Rosenmann
Department of Neurology and the Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel
4 shared publicationsVardiella Meiner
Department of Genetics and Metabolic Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
4 shared publicationsDov Soffer
3 shared publicationsAvinoam Reches
Department of Neurology and the Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel
2 shared publications
Latest Publications
- Open Access
- 11 January 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 470, 123394
Diagnostic clues in herpes encephalitis following radiation therapy
- 11 January 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 470, 123394
Open AccessDiagnostic clues in herpes encephalitis following radiation therapy
- Open Access
- 23 February 2023
- Published by Springer Nature in Research Square
Plasma based biomarkers detect radiation induced neurotoxicity in cancer patients treated for brain metastasis: A Pilot study.
Radiotherapy has an important role in the treatment of brain metastases (BrM) but carries risk of short and/or long-term toxicity, termed radiation-induced neurotoxicity (RIN). As the diagnosis of RIN is crucial for correct pa-tient management, there is an unmet need for reliable biomarkers for RIN. The aim of this proof-of concept study was to determine the utility of brain-derived circulating free DNA (BncfDNA), identified by specific methylation patterns for neurons, astrocytes, and oligodendrocytes, as RIN biomarkers. Twenty-four patients with BrM were monitored clinically and radiologically before, during and after brain radiotherapy, and blood for BncfDNA analysis (98 samples) was concurrently collected. Sixteen patients were treated with whole brain radiotherapy and eight patients with stereotactic radiosurgery. During follow-up nine RIN events were detected, and all correlated with significant increase in BncfDNA levels compared to baseline. Additionally, resolution of RIN correlated with de-crease in BncfDNA. Changes in BncfDNA were independent of tumor response. Elevated BncfDNA levels reflects brain cell injury incurred by radiotherapy, further research is needed to establish BncfDNA as a novel plasma-based biomarker for RIN.
- 23 February 2023
- Published by Springer Nature in Research Square
Open AccessPlasma based biomarkers detect radiation induced neurotoxicity in cancer patients treated for brain metastasis: A Pilot study.
Radiotherapy has an important role in the treatment of brain metastases (BrM) but carries risk of short and/or long-term toxicity, termed radiation-induced neurotoxicity (RIN). As the diagnosis of RIN is crucial for correct pa-tient management, there is an unmet need for reliable biomarkers for RIN. The aim of this proof-of concept study was to determine the utility of brain-derived circulating free DNA (BncfDNA), identified by specific methylation patterns for neurons, astrocytes, and oligodendrocytes, as RIN biomarkers. Twenty-four patients with BrM were monitored clinically and radiologically before, during and after brain radiotherapy, and blood for BncfDNA analysis (98 samples) was concurrently collected. Sixteen patients were treated with whole brain radiotherapy and eight patients with stereotactic radiosurgery. During follow-up nine RIN events were detected, and all correlated with significant increase in BncfDNA levels compared to baseline. Additionally, resolution of RIN correlated with de-crease in BncfDNA. Changes in BncfDNA were independent of tumor response. Elevated BncfDNA levels reflects brain cell injury incurred by radiotherapy, further research is needed to establish BncfDNA as a novel plasma-based biomarker for RIN.
- 3 April 2021
- Published by Springer Nature in neurogenetics
- Vol. 22 (2) , 117-125
Multi-system neurological disorder associated with a CRYAB variant
We report a multiplex family with extended multisystem neurological phenotype associated with a CRYAB variant. Two affected siblings were evaluated with whole exome sequencing, muscle biopsy, laser microdissection, and mass spectrometry-based proteomic analysis. Both patients and their mother manifested a combination of early-onset cataracts, cardiomyopathy, cerebellar ataxia, optic atrophy, cognitive impairment, and myopathy. Whole exome sequencing identified a heterozygous c.458C>T variant mapped to the C-terminal extension domain of the Alpha-crystallin B chain, disrupting its function as a molecular chaperone and its ability to suppress protein aggregation. In accordance with the molecular findings, muscle biopsies revealed subsarcolemmal deposits that appeared dark with H&E and trichrome staining were negative for the other routine histochemical staining and for amyloid with the Congo-red stain. Electron microscopy demonstrated that the deposits were composed of numerous parallel fibrils. Laser microdissection and mass spectrometry-based proteomic analysis revealed that the inclusions are almost exclusively composed of crystallized chaperones/heat shock proteins. Moreover, a structural model suggests that Ser153 could be involved in monomer stabilization, dimer association, and possible binding of partner proteins. We propose that our report potentially expands the complex phenotypic spectrum of alpha B-crystallinopathies with possible effect of a CRYAB variant on the central nervous system.
- 3 April 2021
- Published by Springer Nature in neurogenetics
- Vol. 22 (2) , 117-125
Multi-system neurological disorder associated with a CRYAB variant
We report a multiplex family with extended multisystem neurological phenotype associated with a CRYAB variant. Two affected siblings were evaluated with whole exome sequencing, muscle biopsy, laser microdissection, and mass spectrometry-based proteomic analysis. Both patients and their mother manifested a combination of early-onset cataracts, cardiomyopathy, cerebellar ataxia, optic atrophy, cognitive impairment, and myopathy. Whole exome sequencing identified a heterozygous c.458C>T variant mapped to the C-terminal extension domain of the Alpha-crystallin B chain, disrupting its function as a molecular chaperone and its ability to suppress protein aggregation. In accordance with the molecular findings, muscle biopsies revealed subsarcolemmal deposits that appeared dark with H&E and trichrome staining were negative for the other routine histochemical staining and for amyloid with the Congo-red stain. Electron microscopy demonstrated that the deposits were composed of numerous parallel fibrils. Laser microdissection and mass spectrometry-based proteomic analysis revealed that the inclusions are almost exclusively composed of crystallized chaperones/heat shock proteins. Moreover, a structural model suggests that Ser153 could be involved in monomer stabilization, dimer association, and possible binding of partner proteins. We propose that our report potentially expands the complex phenotypic spectrum of alpha B-crystallinopathies with possible effect of a CRYAB variant on the central nervous system.
- Open Access
- 1 January 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 3 (1) , vdab019
[18F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma
G lioblastoma (GBM) is associated with poor overall survival. Recently, we showed that androgen receptor (AR) protein is overexpressed in 56% of GBM specimens and AR antagonists induced dose-dependent death in several GBM cell lines and significantly reduced tumor growth and prolonged the lifespan of mice implanted with human GBM. 16β-18F-fluoro-5α-dihydrotestosterone ([18F]-FDHT) is a positron emission tomography (PET) tracer used to detect AR expression in prostate and breast cancers. This study was aimed at exploring the ability of [18F]-FDHT-PET to detect AR expression in high-grade gliomas. Twelve patients with suspected high-grade glioma underwent a regular workup and additional dynamic and static [18F]-FDHT-PET/CT. Visual and quantitative analyses of [18 F]-FDHT kinetics in the tumor and normal brain were performed. Mean and maximum (max) standardized uptake values (SUVs) were determined in selected volumes of interest. The patients had surgery or biopsy after PET/CT. AR protein was analyzed in the tumor samples by western blot. Fold change in AR expression was calculated by densitometry analysis. Correlation between imaging and AR protein samples was determined. In six of the 12 patients, [18 F]-FDHT uptake was significantly higher in the tumor than in the normal brain. These patients also had increased AR protein expression within the tumor. Pearson correlation coefficient analysis for the tumor-to-control normal brain uptake ratio in terms of SUVmean versus AR protein expression was positive and significant (R = 0.84; P = .002). [18 F]-FDHT-PET/CT could identify increased AR expression in high-grade glioma.
- 1 January 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 3 (1) , vdab019
Open Access[18F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma
G lioblastoma (GBM) is associated with poor overall survival. Recently, we showed that androgen receptor (AR) protein is overexpressed in 56% of GBM specimens and AR antagonists induced dose-dependent death in several GBM cell lines and significantly reduced tumor growth and prolonged the lifespan of mice implanted with human GBM. 16β-18F-fluoro-5α-dihydrotestosterone ([18F]-FDHT) is a positron emission tomography (PET) tracer used to detect AR expression in prostate and breast cancers. This study was aimed at exploring the ability of [18F]-FDHT-PET to detect AR expression in high-grade gliomas. Twelve patients with suspected high-grade glioma underwent a regular workup and additional dynamic and static [18F]-FDHT-PET/CT. Visual and quantitative analyses of [18 F]-FDHT kinetics in the tumor and normal brain were performed. Mean and maximum (max) standardized uptake values (SUVs) were determined in selected volumes of interest. The patients had surgery or biopsy after PET/CT. AR protein was analyzed in the tumor samples by western blot. Fold change in AR expression was calculated by densitometry analysis. Correlation between imaging and AR protein samples was determined. In six of the 12 patients, [18 F]-FDHT uptake was significantly higher in the tumor than in the normal brain. These patients also had increased AR protein expression within the tumor. Pearson correlation coefficient analysis for the tumor-to-control normal brain uptake ratio in terms of SUVmean versus AR protein expression was positive and significant (R = 0.84; P = .002). [18 F]-FDHT-PET/CT could identify increased AR expression in high-grade glioma.
- Open Access
- 6 September 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (17)
Guaiacol as a drug candidate for treating adult polyglucosan body disease
Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency. To find a treatment for APBD, we screened 1,700 FDA-approved compounds in fibroblasts derived from APBD-modeling GBE1 -knockin mice. Capitalizing on fluorescent periodic acid–Schiff reagent, which interacts with polyglucosans in the cell, this screen discovered that the flavoring agent guaiacol can lower polyglucosans, a result also confirmed in APBD patient fibroblasts. Biochemical assays showed that guaiacol lowers basal and glucose 6-phosphate–stimulated glycogen synthase (GYS) activity. Guaiacol also increased inactivating GYS1 phosphorylation and phosphorylation of the master activator of catabolism, AMP-dependent protein kinase. Guaiacol treatment in the APBD mouse model rescued grip strength and shorter lifespan. These treatments had no adverse effects except making the mice slightly hyperglycemic, possibly due to the reduced liver glycogen levels. In addition, treatment corrected penile prolapse in aged GBE1 -knockin mice. Guaiacol’s curative effects can be explained by its reduction of polyglucosans in peripheral nerve, liver, and heart, despite a short half-life of up to 60 minutes in most tissues. Our results form the basis to use guaiacol as a treatment and prepare for the clinical trials in APBD.
- 6 September 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (17)
Open AccessGuaiacol as a drug candidate for treating adult polyglucosan body disease
Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency. To find a treatment for APBD, we screened 1,700 FDA-approved compounds in fibroblasts derived from APBD-modeling GBE1 -knockin mice. Capitalizing on fluorescent periodic acid–Schiff reagent, which interacts with polyglucosans in the cell, this screen discovered that the flavoring agent guaiacol can lower polyglucosans, a result also confirmed in APBD patient fibroblasts. Biochemical assays showed that guaiacol lowers basal and glucose 6-phosphate–stimulated glycogen synthase (GYS) activity. Guaiacol also increased inactivating GYS1 phosphorylation and phosphorylation of the master activator of catabolism, AMP-dependent protein kinase. Guaiacol treatment in the APBD mouse model rescued grip strength and shorter lifespan. These treatments had no adverse effects except making the mice slightly hyperglycemic, possibly due to the reduced liver glycogen levels. In addition, treatment corrected penile prolapse in aged GBE1 -knockin mice. Guaiacol’s curative effects can be explained by its reduction of polyglucosans in peripheral nerve, liver, and heart, despite a short half-life of up to 60 minutes in most tissues. Our results form the basis to use guaiacol as a treatment and prepare for the clinical trials in APBD.
- 21 July 2015
- Published by Springer Nature in Journal of Neurology
- Vol. 262 (10) , 2346-2351
Frequent misdiagnosis of adult polyglucosan body disease
Adult polyglucosan body disease (APBD) is a rare glycogenosis manifesting progressive spastic paraparesis, sensorimotor polyneuropathy and neurogenic bladder. Misdiagnosis of APBD may lead to unnecessary investigations and to potentially harmful therapeutic interventions. To examine the frequency of misdiagnosis of APBD, we retrospectively reviewed the clinical data of 30 patients diagnosed between 1991 and 2013. Diagnosis was based on the combination of typical clinical and imaging findings, reduced glycogen branching enzyme activity, and the presence of p.Y326S GBE1 mutation. Initial symptoms started in the 5th–6th decade with bladder dysfunction (47 %), gait problems (33 %) or both. Diagnosis of APBD was delayed by 6.8 (±4.8) years. Consistent signs at diagnosis were spasticity in the legs (93 %), decreased or absent ankle reflexes (100 %), bilateral extensor plantar response (100 %) and distal sensory deficit (80 %). Nerve conduction study showed invariable sensorimotor polyneuropathy, and MRI demonstrated cervical spinal cord atrophy (100 %) and leukoencephalopathy (97 %). All 30 patients were initially misdiagnosed. Common misdiagnoses included cerebral small vessel disease (27 %), multiple sclerosis (17 %), amyotrophic lateral sclerosis (17 %) and peripheral neuropathies (20 %). Consequently, 27 % received inappropriate therapy. In addition, lower urinary tract symptoms in 60 % of men were attributed solely to prostatic disorders but did not respond to medical treatment or prostatectomy. These findings suggest that despite limited clinical variability, APBD is invariably misdiagnosed and patients are often mistreated. Physicians’ unfamiliarity with the typical clinical and imaging features of APBD appears as the main reason for misdiagnosis.
- 21 July 2015
- Published by Springer Nature in Journal of Neurology
- Vol. 262 (10) , 2346-2351
Frequent misdiagnosis of adult polyglucosan body disease
Adult polyglucosan body disease (APBD) is a rare glycogenosis manifesting progressive spastic paraparesis, sensorimotor polyneuropathy and neurogenic bladder. Misdiagnosis of APBD may lead to unnecessary investigations and to potentially harmful therapeutic interventions. To examine the frequency of misdiagnosis of APBD, we retrospectively reviewed the clinical data of 30 patients diagnosed between 1991 and 2013. Diagnosis was based on the combination of typical clinical and imaging findings, reduced glycogen branching enzyme activity, and the presence of p.Y326S GBE1 mutation. Initial symptoms started in the 5th–6th decade with bladder dysfunction (47 %), gait problems (33 %) or both. Diagnosis of APBD was delayed by 6.8 (±4.8) years. Consistent signs at diagnosis were spasticity in the legs (93 %), decreased or absent ankle reflexes (100 %), bilateral extensor plantar response (100 %) and distal sensory deficit (80 %). Nerve conduction study showed invariable sensorimotor polyneuropathy, and MRI demonstrated cervical spinal cord atrophy (100 %) and leukoencephalopathy (97 %). All 30 patients were initially misdiagnosed. Common misdiagnoses included cerebral small vessel disease (27 %), multiple sclerosis (17 %), amyotrophic lateral sclerosis (17 %) and peripheral neuropathies (20 %). Consequently, 27 % received inappropriate therapy. In addition, lower urinary tract symptoms in 60 % of men were attributed solely to prostatic disorders but did not respond to medical treatment or prostatectomy. These findings suggest that despite limited clinical variability, APBD is invariably misdiagnosed and patients are often mistreated. Physicians’ unfamiliarity with the typical clinical and imaging features of APBD appears as the main reason for misdiagnosis.
- 1 April 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 339 (1-2) , 210-213
A novel SCARB2 mutation in progressive myoclonus epilepsy indicated by reduced β-glucocerebrosidase activity
- 1 April 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 339 (1-2) , 210-213
A novel SCARB2 mutation in progressive myoclonus epilepsy indicated by reduced β-glucocerebrosidase activity
- Open Access
- 5 February 2013
- Published by Oxford University Press (OUP) in Brain
- Vol. 136 (7) , e238
MYH2 mutation in recessive myopathy with external ophthalmoplegia linked to chromosome 17p13.1-p12
Sir, in 2005, we described a new autosomal recessive myopathy with external ophthalmoplegia in 16 subjects of eight families from a large and highly inbred Arab community near Jerusalem (Lossos et al., 2005). Characteristic clinical features of this disorder include conjugate non-restrictive ocular motility impairment without ptosis, mild facial and limb muscle weakness and scoliosis. The major pathological finding on skeletal muscle biopsy was marked Type 1 fibre predominance. A genome-wide search for areas of homozygosity identified linkage with chromosome 17p13.1-p12 markers defining a critical region of 12 cM encompassing an ordered cluster of six myosin heavy-chain genes. Direct sequencing of the MYH2, reported by that time to be involved in autosomal-dominant myosin heavy-chain (MyHC) IIa myopathy (Martinsson et al., 2000), showed no exonic mutations, and the genetic cause of this disorder remained unknown.
- 5 February 2013
- Published by Oxford University Press (OUP) in Brain
- Vol. 136 (7) , e238
Open AccessMYH2 mutation in recessive myopathy with external ophthalmoplegia linked to chromosome 17p13.1-p12
Sir, in 2005, we described a new autosomal recessive myopathy with external ophthalmoplegia in 16 subjects of eight families from a large and highly inbred Arab community near Jerusalem (Lossos et al., 2005). Characteristic clinical features of this disorder include conjugate non-restrictive ocular motility impairment without ptosis, mild facial and limb muscle weakness and scoliosis. The major pathological finding on skeletal muscle biopsy was marked Type 1 fibre predominance. A genome-wide search for areas of homozygosity identified linkage with chromosome 17p13.1-p12 markers defining a critical region of 12 cM encompassing an ordered cluster of six myosin heavy-chain genes. Direct sequencing of the MYH2, reported by that time to be involved in autosomal-dominant myosin heavy-chain (MyHC) IIa myopathy (Martinsson et al., 2000), showed no exonic mutations, and the genetic cause of this disorder remained unknown.
- Open Access
- 1 May 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (5) , 756-760
Hereditary Spastic Paraplegia With Thin Corpus Callosum
Hereditary spastic paraplegia (HSP) with thin corpus callosum (TCC) (Online Mendelian Inheritance in Man [OMIM] #604360) is an autosomal recessive form of complicated HSP characterized clinically by slowly progressive spastic paraparesis and mental deterioration beginning in the second decade of life.1 Additional manifestations include urinary incontinence, sensory deficit in the legs, late distal amyotrophy, occasional seizures, extrapyramidal signs, and cerebellar ataxia. Although the appearance of TCC on cerebral magnetic resonance imaging is typical of HSP-TCC,1 it also occurs in some of the other HSPs, including those related to SPG7,2SPG21,3 and SPG4,4 and in peripheral neuropathy with agenesis of the corpus callosum,5 making genetic analysis essential for diagnosis.
- 1 May 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (5) , 756-760
Open AccessHereditary Spastic Paraplegia With Thin Corpus Callosum
Hereditary spastic paraplegia (HSP) with thin corpus callosum (TCC) (Online Mendelian Inheritance in Man [OMIM] #604360) is an autosomal recessive form of complicated HSP characterized clinically by slowly progressive spastic paraparesis and mental deterioration beginning in the second decade of life.1 Additional manifestations include urinary incontinence, sensory deficit in the legs, late distal amyotrophy, occasional seizures, extrapyramidal signs, and cerebellar ataxia. Although the appearance of TCC on cerebral magnetic resonance imaging is typical of HSP-TCC,1 it also occurs in some of the other HSPs, including those related to SPG7,2SPG21,3 and SPG4,4 and in peripheral neuropathy with agenesis of the corpus callosum,5 making genetic analysis essential for diagnosis.
- Open Access
- 1 February 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (2) , 278-280
Phenotypic Variability Among Adult Siblings With Sjögren-Larsson Syndrome
Sjögren-Larsson syndrome (SLS) (Online Mendelian Inheritance in Man 270200) is an autosomal recessive disorder characterized by congenital ichthyosis, mental retardation, spastic paraparesis, and leukoencephalopathy.1 Additional manifestations include perimacular glistening white dots, photophobia, seizures, and the development of leg contractures. The neurological features of SLS appear in the first few years of life and then seem to stabilize.2 Most described patients have been children,2,3 and less is known about the long-term clinical course in adults.
- 1 February 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (2) , 278-280
Open AccessPhenotypic Variability Among Adult Siblings With Sjögren-Larsson Syndrome
Sjögren-Larsson syndrome (SLS) (Online Mendelian Inheritance in Man 270200) is an autosomal recessive disorder characterized by congenital ichthyosis, mental retardation, spastic paraparesis, and leukoencephalopathy.1 Additional manifestations include perimacular glistening white dots, photophobia, seizures, and the development of leg contractures. The neurological features of SLS appear in the first few years of life and then seem to stabilize.2 Most described patients have been children,2,3 and less is known about the long-term clinical course in adults.